Biotech entity

Integra LifeSciences

Company IART

All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Integra LifeSciences, all published on February 26, 2026.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · Integra LifeSciences

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Integra LifeSciences

All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Integra LifeSciences, all published on February 26, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Integra LifeSciences. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Earnings

    Company reports quarterly results and provides updates on quality remediation and 2026 outlook.

  2. New CEO Appointment

    Mojdeh Poul succeeds Jan De Witte as President and CEO of Integra LifeSciences.

  3. Boston Plant Recall

    Integra initiates voluntary recall of SurgiMend and PriMatrix products due to manufacturing issues.

Stories mentioning Integra LifeSciences 1

Pharma Neutral

Integra LifeSciences Navigates Operational Recovery Amid CEO Transition

Integra LifeSciences reported its latest quarterly results, highlighting a period of strategic stabilization and operational remediation. While the company continues to address manufacturing challenges at its Boston facility, the appointment of new leadership and steady performance in its Codman Specialty Surgical segment signal a path toward long-term recovery.

2 sources

Integra LifeSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.